Trial Outcomes & Findings for Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test (NCT NCT01892657)

NCT ID: NCT01892657

Last Updated: 2022-08-01

Results Overview

Subjects were patched 9 times at 48 hour to 72 hour intervals and graded for erythema and elevated responses (edema, papules, vesicles, bullae) on a 4 point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). 12 to 24 hours after the last patch application, a challenge patch was applied at the same site and a challenge patch was applied to an alternate site. Both were graded for the same criteria at 48 hours and at 96 hours. A total of 11 patches were applied to each subject. All patches were removed after 48 hours.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

128 participants

Primary outcome timeframe

3 consecutive weeks

Results posted on

2022-08-01

Participant Flow

Subjects were screened at a single US center.

Participant milestones

Participant milestones
Measure
Facial Moisturizer With SPF 50+
All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
Overall Study
STARTED
128
Overall Study
COMPLETED
110
Overall Study
NOT COMPLETED
18

Reasons for withdrawal

Reasons for withdrawal
Measure
Facial Moisturizer With SPF 50+
All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
Overall Study
Withdrawal by Subject
6
Overall Study
Protocol Violation
12

Baseline Characteristics

Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Facial Moisturizer With SPF 50+
n=110 Participants
All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
109 Participants
n=5 Participants
Age, Categorical
>=65 years
1 Participants
n=5 Participants
Age, Continuous
44.0 years
STANDARD_DEVIATION 13.68 • n=5 Participants
Sex: Female, Male
Female
86 Participants
n=5 Participants
Sex: Female, Male
Male
24 Participants
n=5 Participants
Race/Ethnicity, Customized
African American
10 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian
3 Participants
n=5 Participants
Race/Ethnicity, Customized
Caucasian
71 Participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
23 Participants
n=5 Participants
Race/Ethnicity, Customized
Caucasian/Hispanic
3 Participants
n=5 Participants
Region of Enrollment
United States
110 participants
n=5 Participants

PRIMARY outcome

Timeframe: 3 consecutive weeks

Subjects were patched 9 times at 48 hour to 72 hour intervals and graded for erythema and elevated responses (edema, papules, vesicles, bullae) on a 4 point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). 12 to 24 hours after the last patch application, a challenge patch was applied at the same site and a challenge patch was applied to an alternate site. Both were graded for the same criteria at 48 hours and at 96 hours. A total of 11 patches were applied to each subject. All patches were removed after 48 hours.

Outcome measures

Outcome measures
Measure
Patch 1
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Patch 2
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Patch 3
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Patch 4
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Patch 5
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Patch 6
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Patch 7
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Patch 8
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Patch 9
n=110 Participants
Subjects received a patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+
Challenge Patch (Original Site) - 48 Hours
n=110 Participants
The challenge patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+ applied to the original application site was graded at 48 hours.
Challenge Patch (Original Site) - 96 Hours
n=110 Participants
The challenge patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+ applied to the original application site was graded again at 96 hours.
Challenge Patch (Alternate Site) - 48 Hours
n=110 Participants
A challenge patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+ applied to an alternate application site was graded at 48 hours.
Challenge Patch (Alternate Site) - 96 Hours
n=110 Participants
A challenge patch dosed with 100 microliters of Cetaphil Daily Facial Moisturizer with SPF 50+ applied to an alternate application site was graded again at 96 hours.
Area of Erythema and Elevated Responses of Skin to Product
None
91 participants
68 participants
33 participants
42 participants
39 participants
20 participants
33 participants
33 participants
23 participants
78 participants
85 participants
86 participants
95 participants
Area of Erythema and Elevated Responses of Skin to Product
Mild
19 participants
41 participants
72 participants
68 participants
69 participants
82 participants
72 participants
72 participants
78 participants
31 participants
24 participants
23 participants
12 participants
Area of Erythema and Elevated Responses of Skin to Product
Moderate
0 participants
1 participants
5 participants
0 participants
2 participants
8 participants
5 participants
5 participants
9 participants
1 participants
1 participants
1 participants
3 participants

Adverse Events

Facial Moisturizer With SPF 50+

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Elizabeth M. Nieman, Medical Information Specialist

Galderma Laboratories, L.P.

Phone: 817-961-5130

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60